Celera Genomics to Provide Financial and Business Outlook at Its Analyst and Investor Meeting Today.

ROCKVILLE, Md. -- Celera Anticipates 35 to 40 Percent End-User Sales Growth and a Net Loss of $28 to $35 million for Fiscal 2007, and Targets Profitability by the End of Fiscal 2008

Celera Genomics (NYSE:CRA), an Applera Corporation business, today plans to provide analysts and investors with an overview of its strategy for the business following the recent integration of Celera Diagnostics into Celera Genomics, and to update the investment community on the status of key products and development programs. Celera management, led by Kathy Ordonez, President of Celera, will present its strategy for growth, and as part of this presentation, will update its outlook for cash and short-term investments and end-user sales for fiscal year 2006 and provide its financial and business outlook for fiscal 2007.

Outlook

At the end of fiscal 2006, Celera Genomics expects to have cash and short-term investments in the range of $560 to $570 million. This outlook excludes potential proceeds from any partnering or sale of its small molecule programs and associated assets.

Celera Genomics anticipates that its fiscal 2007 financial performance will be affected by, among other things, continued growth in demand for current and new diagnostic products and potential revenue from technology licenses and collaborations. Subject to the inherent uncertainty associated with these factors, Celera Genomics has the following expectations regarding its financial performance for fiscal 2007:

--End-user sales of products sold through Celera's alliance with Abbott Laboratories are anticipated to increase by 35 to 40 percent over fiscal 2006, which are expected to be $75 to 85 million.

--Revenues from licensing and collaborations are anticipated to be $8 to $12 million.

--Reported revenues are anticipated to be $40 to 45 million.

--Net loss is anticipated to be $28 to $35 million.

--Celera Genomics expects to consume approximately $45 to $55 million in cash and short-term investments from operating activities, growth in instrument placements, and cash costs related to the fiscal 2006 restructuring.

Celera Genomics anticipates that it will reach profitability by the end of fiscal 2008.

Fiscal 2011 Financial Goals

Celera has established the following financial goals for fiscal 2011: end-user sales of approximately $400 to $500 million; reported revenues of approximately $160 to $200 million; and operating profitability of approximately 15 to 20 percent of reported revenues.

The information contained in this press release regarding future financial and business performance is being provided solely for purposes of the special Analyst and Investor Meeting and is not intended to reflect a departure from the Company's normal policy of providing guidance only once each quarter when financial results are announced. This information and the other information contained in this release reflect known facts, circumstances, assumptions, and expectations as of June 22, 2006, and the Company undertakes no obligation to update any such information unless required by law.

Many factors could cause actual results to differ materially from projected or historical results. In addition to those set forth above, risks and uncertainties that may affect Celera Genomics' financial performance are detailed in the Forward-Looking Statements section of this release.

Webcast

The Analyst and Investor Meeting will be webcast and will begin at 9:00 a.m. Eastern Time. Interested parties may access the live webcast and replay by visiting the Investors & Media section of either the Celera Genomics website at www.celera.com or the Applera website at www.applera.com. It is suggested that participants access the webcast 15 minutes before the start of the live broadcast. The webcast replay will be archived until September 22, 2006 on the Presentations page of the Investors & Media section of each website.

About Celera Genomics and Applera Corporation

Applera Corporation consists of two operating groups. The Celera Genomics Group uses proprietary genomics and proteomics discovery platforms to develop molecular diagnostic products and to identify and validate novel drug targets. Celera maintains a strategic alliance in molecular diagnostics with Abbott. In addition, Celera is developing new molecular diagnostic and pharmacogenomic assays outside of its alliance with Abbott. Therapeutic antibodies against Celera-discovered drug targets are being advanced through strategic partnerships. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at http://www.celera.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "should," "anticipate," and "intend," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses, including the Celera Diagnostic business that is now fully owned by Celera Genomics, include but are not limited to: (1) Celera Genomics expects operating losses for the foreseeable future; (2) Celera Genomics' unproven ability to discover, develop, or commercialize proprietary therapeutic products; (3) Celera Genomics' unproven ability to discover, develop, or commercialize new proprietary diagnostic products; (4) the risk that clinical trials of therapeutic or diagnostic products that Celera Genomics develops will not proceed as anticipated, may take several years and be very expensive, or may not be successful, (5) the risk that therapeutic or diagnostic products will not receive required regulatory clearances or approvals; (6) the uncertainty that Celera Genomics' therapeutic or diagnostic products will be accepted and adopted by the market, including the risk that these products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for these products from third party payors such as private insurance companies and government insurance plans; (7) reliance on existing and future collaborations with other companies, including, in the case of the diagnostics business, the strategic alliance with Abbott, which may not be successful; (8) reliance on access to biological materials and related clinical and other information, which may be in limited supply or access to which may be limited; (9) intense competition in the therapeutic and diagnostic industries in which Celera Genomics operates; (10) potential product liability or other claims against Celera Genomics as a result of the testing or use of its therapeutic or diagnostic products; (11) reliance on scientific and management personnel having the training and technical backgrounds necessary for Celera Genomics' business, and also on collaborations with scientific and clinical experts at academic and other institutions who may not be available to Celera Genomics or who may compromise the confidentiality of Celera Genomics' proprietary information; (12) potential liabilities related to the use of hazardous materials; (13) uncertainty of the availability of intellectual property protection, limitations on Celera Genomics' ability to protect trade secrets, the risk of infringement claims, and the possibility that Celera Genomics may need to license intellectual property from third parties to avoid or settle such claims; (14) Celera Genomics' dependence on the operation of computer hardware, software, and Internet applications and related technology; (15) legal, ethical, and social issues which could affect demand for Celera Genomics' therapeutic or diagnostic products; (16) risks associated with future acquisitions by Celera Genomics, including that they may be unsuccessful; (17) uncertainty of the outcome of existing stockholder litigation; (18) Celera Genomics' limited commercial manufacturing experience and capabilities and its reliance on a single principal manufacturing facility for manufacturing its diagnostic products; (19) Celera Genomics' reliance on a single supplier or a limited number of suppliers for key components of certain of its products; (20) the risk of earthquakes, which could interrupt operations; (21) the risk that Celera Genomics will not be successful in its efforts to partner or sell its small molecule drug development programs; and (22) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.